Ireland’s Genable Technologies Completes €5M Series B Financing
November 11, 2011
Amarin Announces NDA Submission for AMR101 for the Treatment of Patients with Very High Triglycerides
September 26, 2011
Amarin Announces Agreement From FDA On Special Protocol Assessment For Amr101 Outcomes Study
August 10, 2011
Civitas Therapeutics Secures $5M in Financing - Accelerating Parkinson’s disease program
July 12, 2011
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
July 05, 2011
Amarin Announces Global Supply Network for AMR101
May 31, 2011
Additional Detail of Successful MARINE Phase III Trial to be Presented at the National Lipid Association 2011 Annual Scientific Sessions
May 19, 2011
Amarin-Sponsored Posters to be Presented Today at the National Lipid Association 2011 Annual Scientific Sessions
May 19, 2011
Dr. Leon Hooftman Appointed Chief Medical Officer As Opsona Therapeutics Transitions Into The Clinic
May 06, 2011
European Commission Awards Eur 5.9m To Opsona Therapeutics For Clinical Development Of Lead Drug Candidate Opn-305
May 06, 2011
Opsona Therapeutics Appoints Chairman Dr. Bernd R. Seizinger As Executive Chairman; Dr. Mark Heffernan Resigns As Ceo But Remains As Non-Executive Director
May 06, 2011
Amarin’s AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints
April 18, 2011
Amarin Corporation announces the pricing of an underwritten public offering
January 06, 2011
Cappella Medical Systems Announces First Placements of its New Dual Marker Sideguard® System
December 20, 2010
Amarin Completes Patient Randomization in Phase 3 ANCHOR Trial
December 15, 2010
Cappella Medical Systems Wins Top Medical Technology Industry Awards
December 07, 2010
Amarin’s AMR101 Meets Pivotal Phase 3 Study Endpoints
November 29, 2010
Amarin Corporation Appoints Kristine Peterson to Board of Directors
November 18, 2010
Amarin Corporation Announces Senior Management Changes
November 10, 2010
Amarin Reports Third Quarter 2010 Financial Results and Positively Updates Phase 3 Guidance
November 10, 2010
Cappella, Inc. completed the first tranche of a €10.5 million Series D investment
November 01, 2010
Luis Malave Joins Palyon Corporation as CEO
August 24, 2010
Insulet Announces Departure of Chief Operating Officer
August 18, 2010
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
August 17, 2010
AMARIN REPORTS Q2 2010 RESULTS -MARINE trial results due early 2011; ANCHOR trial >50% randomized - Conference call today
August 10, 2010
Amarin’s Amr101 Pivotal Phase 3 Marine Clinical Trial Completes Patient Enrollment And Randomization - Trial Guidance Positively Updated
August 10, 2010
Eamonn Hobbs Accepts Appointment as Chairman of the Board of Directors of Cappella
June 22, 2010
David Blossom joins Cappella as Vice President, Commercial Operations
June 14, 2010
Amarin Reports Q1 2010 Results
May 13, 2010
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
December 02, 2009
Cappella, Inc. Announces Initiation of Sideguard 3
November 16, 2009
Amarin Appoints John F. Thero as Chief Financial Officer
November 06, 2009
Amarin Appoints Medpace As Cro For Two Phase 3 Cardiovascular Trials
October 19, 2009
Amarin Announces Completion Of $70 Million Private Placement
October 19, 2009
Amarin Announces $70 Million Private Placement
October 13, 2009
Amarin Announces Changes to Its Board And Management Team
October 13, 2009
Cappella Inc. Secures $17.3 Million Series C Investment
June 15, 2009
Nextech Venture participates in the $24m financing of Palyon Medical
May 19, 2009
Palyon Medical Corporation Secures $21 Million Series A Investment
April 29, 2009
Opsona Therapheutics Closes €18M Funding
February 18, 2009
Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia
July 22, 2008
Amarin announces private placement for up to $60 million
May 14, 2008
Launch of Fountain Healthcare Partners, a Life Science Venture Capital Firm
April 29, 2008
Copyright © 2008-2012, Fountain HP. Designed and developed by
Web Design Sligo
WSI Web Excel
67
